Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306).

Dominik Paul Modest,Sebastian Stintzing,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christoph Kahl,Gernot Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Swantje Held,Clemens Giessen-Jung,Andreas Jung,Thomas Kirchner,Volker Heinemann

Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306).

2017

Dominik Paul Modest
Sebastian Stintzing
Ludwig Fischer von Weikersthal
Thomas Decker
Alexander Kiani
Ursula Vehling-Kaiser
Salah-Eddin Al-Batran
Tobias Heintges
Christoph Kahl
Gernot Seipelt
Frank Kullmann
Martina Stauch
Werner Scheithauer
Swantje Held
Clemens Giessen-Jung
Andreas Jung
Thomas Kirchner
Volker Heinemann

3525Background: FIRE3 compared 1st-line therapy with FOLFIRI plus either cetuximab (arm A) or bevacizumab (arm B) in 592 patients (pts) with KRAS exon 2 wild-type metastatic colorectal cancer (mCRC...

Keywords:

FOLFIRI
Cetuximab
Bevacizumab
Oncology
Primary tumor
Second-line therapy
Colorectal cancer
Pathology
Medicine
Internal medicine
in patient
initial treatment
KRAS

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations